NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Forecast, Price & News $0.18 -0.01 (-5.35%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.18▼$0.1950-Day Range$0.15▼$0.2652-Week Range$0.14▼$1.61Volume219,876 shsAverage Volume353,666 shsMarket Capitalization$13.17 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Akari Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,454.6% Upside$2.75 Price TargetShort InterestHealthy0.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector678th out of 1,006 stocksPharmaceutical Preparations Industry345th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAkari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.75, Akari Therapeutics has a forecasted upside of 1,454.6% from its current price of $0.18.Amount of Analyst CoverageAkari Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.31% of the outstanding shares of Akari Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently increased by 104.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKTX. Previous Next 2.5 News and Social Media Coverage News SentimentAkari Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Akari Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for AKTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.59% of the stock of Akari Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Akari Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akari Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akari Therapeutics (NASDAQ:AKTX) StockAkari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.Read More Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKTX Stock News HeadlinesMay 27, 2023 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Increase in Short InterestMay 26, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.comJune 1, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 18, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.comMay 16, 2023 | finance.yahoo.comAkari Therapeutics to Participate in A.G.P.’s Virtual Healthcare ConferenceMay 12, 2023 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Decrease in Short InterestMay 9, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.comMay 1, 2023 | finance.yahoo.comAkari Therapeutics Reports Full-Year 2022 Financial Results and HighlightsJune 1, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 1, 2023 | finance.yahoo.comAkari Therapeutics Reports Full-Year 2022 Financial Results and HighlightsApril 25, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price RequirementApril 25, 2023 | finance.yahoo.comAkari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price RequirementApril 23, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.comApril 19, 2023 | finance.yahoo.comInsiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22mApril 18, 2023 | americanbankingnews.comAkari Therapeutics, Plc (NASDAQ:AKTX) Short Interest UpdateApril 14, 2023 | finance.yahoo.comAkari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet NeedsApril 11, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and OphthalmologyApril 11, 2023 | finance.yahoo.comAkari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and OphthalmologyApril 3, 2023 | finance.yahoo.comAkari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual MeetingMarch 31, 2023 | msn.comEuropean Equities Close Out Strong Week Higher in Friday TradingMarch 30, 2023 | msn.comEuropean Equities Rally in Thursday TradingMarch 30, 2023 | benzinga.comAkari Therapeutics Stock (NASDAQ:AKTX), DividendsMarch 30, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics, Plc Announces $4 Million Registered Direct OfferingMarch 30, 2023 | finance.yahoo.comAkari Therapeutics, Plc Announces $4 Million Registered Direct OfferingMarch 30, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.comMarch 29, 2023 | finance.yahoo.comPoland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical StudyMarch 27, 2023 | msn.comBank Stock Recovery Supports American Depositary Receipts of European EquitiesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKTX Company Calendar Last Earnings3/31/2020Today5/31/2023Next Earnings (Estimated)7/19/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees9Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.75 High Stock Price Forecast$4.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+1,454.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book8.85Miscellaneous Outstanding Shares74,450,000Free Float28,440,000Market Cap$13.17 million OptionableNot Optionable Beta1.31 Key ExecutivesRachelle JacquesPresident, Chief Executive Officer & DirectorMelissa Bradford-KlugChief Operating OfficerTorsten HombeckChief Financial & Accounting OfficerMiles NunnChief Scientific OfficerJohn F. NeylanChief Medical Officer & Executive Vice PresidentKey CompetitorsVirios TherapeuticsNASDAQ:VIRIProcessa PharmaceuticalsNASDAQ:PCSAIndaptus TherapeuticsNASDAQ:INDPInfinity PharmaceuticalsNASDAQ:INFIAeterna ZentarisNASDAQ:AEZSView All CompetitorsInstitutional OwnershipSabby Management LLCBought 4,273,528 shares on 5/16/2023Ownership: 10.668%Renaissance Technologies LLCBought 228,100 shares on 5/12/2023Ownership: 0.381%View All Institutional Transactions AKTX Stock - Frequently Asked Questions Should I buy or sell Akari Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares. View AKTX analyst ratings or view top-rated stocks. What is Akari Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price targets for Akari Therapeutics' stock. Their AKTX share price forecasts range from $1.50 to $4.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 1,454.6% from the stock's current price. View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts. How have AKTX shares performed in 2023? Akari Therapeutics' stock was trading at $0.4699 at the start of the year. Since then, AKTX shares have decreased by 62.4% and is now trading at $0.1769. View the best growth stocks for 2023 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 228,600 shares, an increase of 104.5% from the April 30th total of 111,800 shares. Based on an average trading volume of 485,100 shares, the days-to-cover ratio is presently 0.5 days. View Akari Therapeutics' Short Interest. When is Akari Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023. View our AKTX earnings forecast. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.25. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). What is Akari Therapeutics' stock symbol? Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX." Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (10.67%) and Renaissance Technologies LLC (0.38%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akari Therapeutics' stock price today? One share of AKTX stock can currently be purchased for approximately $0.18. How much money does Akari Therapeutics make? Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $13.17 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. How can I contact Akari Therapeutics? Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352. This page (NASDAQ:AKTX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.